Drug
Bmab1800
Bmab1800: highest development phase Phase 1, developed by Biocon. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Biocon
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bmab1800 NCT07581509 | Phase 1 | Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) |
Latest
No recent events.
Follow Bmab1800 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.